DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850



CENTER FOR DRUG AND HEALTH PLAN CHOICE

TO: All Part D Plan Sponsors

FROM: Cynthia G. Tudor, Ph.D., Director, Medicare Drug Benefit and C & D Data Group

Jeffrey Kelman, M.D., Chief Medical Officer

SUBJECT: Early Refill Edits on Topical Ophthalmic Products

DATE: October 6, 2009

The Centers for Medicare & Medicaid Services (CMS) is issuing this guidance in response to questions and concerns we have received regarding the application of early refill edits (i.e. refill-too-soon edits) to topical ophthalmic products. CMS recognizes that early refill edits are an important utilization management tool used to promote compliance and prevent waste. However, it is equally important that Part D sponsors implement such edits in a manner that does not unreasonably put beneficiaries at risk of interruptions in drug therapy that potentially have serious consequences.

Part D sponsors need to take into consideration differences that some dosage forms, such as topical ophthalmics, present when establishing early refill edits. Edits based on an algorithm that is appropriate for tablets and capsules are not necessarily appropriate for other dosage forms for which administration is not as easily measured and controlled. This is not to say that Part D sponsors should not implement early refill edits for such medications, especially given that these edits can identify inappropriate use, but it does mean that such edits need to reasonably accommodate waste that can be anticipated given the nature of these products and their self-administration among the Medicare patient population. Part D sponsors also should be prepared to allow overrides of these edits on a case-by-case basis when appropriate and necessary to prevent unintended interruptions in drug therapy.

If you have any questions regarding this guidance, please contact Craig Miner at 410-786-7937 or craig.miner@cms.hhs.gov.